Initial Efficacy and Safety Results from ENGOT-Ov60/GOG-3052/ramp 201: A phase 2 study of avutometinib (vs-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC) Meeting Abstract
| Authors: | Banerjee, S. N.; Ring, K. L.; Van Niewenhuysen, E.; Fabbro, M.; Aghajanian, C.; Oaknin, A.; Colombo, N.; Santin, A. D.; Clamp, A. R.; Moore, K. N.; Rose, P. G.; David, O. M.; Chon, H. S.; Salinas, E. A.; Prendergast, E. N.; Lustgarten, S.; Rodrigues, M.; Gennigens, C.; Monk, B. J.; Grisham, R. N. |
| Abstract Title: | Initial Efficacy and Safety Results from ENGOT-Ov60/GOG-3052/ramp 201: A phase 2 study of avutometinib (vs-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC) |
| Meeting Title: | 2023 International Meeting of the European Society of Gynaecological Oncology (ESGO) |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 33 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2023 Sep 28-Oct 1 |
| Meeting Location: | Istanbul, Turkey |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2023-09-01 |
| Start Page: | A20 |
| End Page: | A21 |
| Language: | English |
| ACCESSION: | WOS:001264297900030 |
| DOI: | 10.1136/ijgc-2023-ESGO.29 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 523 -- Source: Wos |
